Literature DB >> 19652940

Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio.

Robert Pichler1, Konstantin Sfetsos, Birgit Badics, Sabrina Gutenbrunner, Jörg Berg, Josef Auböck.   

Abstract

Vitiligo is a disorder of pigmentation associated with an autoimmune-mediated loss of melanocytes from the epidermis. Humoral immunity and the involvement of cellular immunity have been investigated in the pathogenesis of vitiligo. We evaluated the role of pro-inflammatory cytokines and lymphocyte fractions in peripheral blood in a cohort of Austrian patients with vitiligo. Morning blood samples from 40 patients with vitiligo were collected. Twenty-one patients had active and 19 had stable vitiligo disease. All patients were suffering from non-segmental vitiligo at different stages of the disease. Sixteen persons presented with an additional autoimmune thyroid disease. To evaluate a possible involvement of proinflammatory cytokines in vitiligo we measured sTNF-RI (soluble tumour necrosis factor receptor I), IL-6 and additionally CIC (circulating immune complexes). We compared these findings to the data from matched normal persons. To investigate the mechanisms of cellular immunity, peripheral blood cell count and lymphocyte subtype analysis by flow cytometry were done. sTNF-RI, IL-6 and CIC serum levels were in the normal range. In the patient group median sTNF-RI level was 1.5 ng/ml and median CIC level was 35.2 microg/ml, and no statistically significant differences to the control group were observed. Median IL-6 level in vitiligo patients was 2.7 pg/ml and in the normal range-but higher than the median level of 0.5 pg/ml observed in normal persons (p < 0.001). Absolute and relative counts of lymphocyte subtypes were normal. The ratio of CD4+/CD8+ T-cells had an elevated median value of 2.6 [quartiles 2.0; 3.1]. 61% of the vitiligo patients had a ratio higher than 2.4, which was the normal cut-off point. In most vitiligo patients the balance of cytotoxic/suppressor and helper/inducer T-cells in peripheral blood is disturbed which might lead to a predominance of T-cell subtypes in the intracutaneous site of autoimmune melanocyte loss.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652940     DOI: 10.1007/s10354-009-0699-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  22 in total

Review 1.  Autoimmune melanocyte destruction in vitiligo.

Authors:  R van den Wijngaard; A Wankowicz-Kalinska; S Pals; J Weening; P Das
Journal:  Lab Invest       Date:  2001-08       Impact factor: 5.662

2.  Cytomegalovirus infection in central European vitiligo patients?

Authors:  Robert Pichler; Konstantin Sfetsos; Josef Auböck; Birgit Badics; Sabrina Gutenbrunner; Jörg Berg
Journal:  Autoimmunity       Date:  2005-03       Impact factor: 2.815

Review 3.  Clinical and laboratory aspects of thyroid autoantibodies.

Authors:  David Sinclair
Journal:  Ann Clin Biochem       Date:  2006-05       Impact factor: 2.057

Review 4.  Effector lymphocytes in autoimmunity.

Authors:  P Santamaria
Journal:  Curr Opin Immunol       Date:  2001-12       Impact factor: 7.486

5.  New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions.

Authors:  Silvia Moretti; Adelina Spallanzani; Lauretta Amato; Giuseppe Hautmann; Isabella Gallerani; Massimo Fabiani; Paolo Fabbri
Journal:  Pigment Cell Res       Date:  2002-04

Review 6.  Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.

Authors:  Thomas Dörner
Journal:  J Rheumatol Suppl       Date:  2006-05

7.  Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo.

Authors:  Jiri Trcka; Yoichi Moroi; Raphael A Clynes; Stacie M Goldberg; Amy Bergtold; Miguel Angel Perales; Minghe Ma; Cristina R Ferrone; Michael C Carroll; Jeffrey V Ravetch; Alan N Houghton
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

8.  Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo.

Authors:  N Mozzanica; M L Villa; S Foppa; G Vignati; A Cattaneo; R Diotti; A F Finzi
Journal:  J Am Acad Dermatol       Date:  1992-05       Impact factor: 11.527

9.  The role of helper and regulatory T cells in the pathogenesis of vitiligo.

Authors:  Pinar Y Basak; Ali K Adiloglu; Ali Murat Ceyhan; Tekin Tas; Vahide B Akkaya
Journal:  J Am Acad Dermatol       Date:  2008-11-20       Impact factor: 11.527

10.  Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo.

Authors:  Anna Wańkowicz-Kalińska; René M J G J van den Wijngaard; Bert J Tigges; Wiete Westerhof; Graham S Ogg; Vincenzo Cerundolo; Walter J Storkus; Pranab K Das
Journal:  Lab Invest       Date:  2003-05       Impact factor: 5.662

View more
  11 in total

1.  Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.

Authors:  Li Zhou; Kai Li; Yu-Ling Shi; Iltefat Hamzavi; Tian-Wen Gao; Marsha Henderson; Richard H Huggins; Oma Agbai; Bassel Mahmoud; Xiaofan Mi; Henry W Lim; Qing-Sheng Mi
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

2.  Evaluation of Histologically and Histochemically Proven Cases of Vitiligo and its Correlation with CD4+ and CD8+ Lymphocyte Counts using Flow Cytometry.

Authors:  Moninder Kaur; Permeet Kaur Bagga; Tejinder Kaur; Amarjit Singh Kataria
Journal:  J Clin Diagn Res       Date:  2017-05-01

3.  CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.

Authors:  Michael P Pender
Journal:  Autoimmune Dis       Date:  2012-01-24

4.  Hypothesis: zinc can be effective in treatment of vitiligo.

Authors:  Nooshin Bagherani; Reza Yaghoobi; Mohammad Omidian
Journal:  Indian J Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.494

5.  Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients.

Authors:  Suman Singh; Usha Singh; S S Pandey
Journal:  Indian J Dermatol       Date:  2012-01       Impact factor: 1.494

6.  Role of Fatty Acids Intake in Generalized Vitiligo.

Authors:  Seyedeh-Masomeh Derakhshandeh-Rishehri; Motahar Heidari-Beni; Fariba Jaffary; Gholamreza Askari; Mohammadali Nilfroshzade; Neda Adibi
Journal:  Int J Prev Med       Date:  2019-05-06

7.  Therapeutic effects of iNOS inhibition against vitiligo in an animal model.

Authors:  Hamid Mansourpour; Katayoun Ziari; Sahar Kalantar Motamedi; Amin Hassan Poor
Journal:  Eur J Transl Myol       Date:  2019-08-06

8.  Analysis of oxidative stress status, catalase and catechol-O-methyltransferase polymorphisms in Egyptian vitiligo patients.

Authors:  Dina A Mehaney; Hebatallah A Darwish; Rehab A Hegazy; Mohammed M Nooh; Amira M Tawdy; Heba I Gawdat; Maha M El-Sawalhi
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

9.  T-cell regulation in Erythema Nodosum Leprosum.

Authors:  Edessa Negera; Stephen L Walker; Kidist Bobosha; Rawleigh Howe; Abraham Aseffa; Hazel M Dockrell; Diana N Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2017-10-09

10.  Prolonged Peripheral Immunosuppressive Responses as Consequences of Random Amphetamine Treatment, Amphetamine Withdrawal and Subsequent Amphetamine Challenges in Rats.

Authors:  Wojciech Glac; Joanna Dunacka; Beata Grembecka; Grzegorz Świątek; Irena Majkutewicz; Danuta Wrona
Journal:  J Neuroimmune Pharmacol       Date:  2021-02-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.